Demographic and clinical characteristics of gastric cancer patients in north of Iran, Mazandaran province, ۲۰۰۸-۲۰۱۴

Publish Year: 1393
نوع سند: مقاله ژورنالی
زبان: English
View: 38

This Paper With 5 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_PBRE-1-1_004

تاریخ نمایه سازی: 10 دی 1402

Abstract:

Gastric cancer has been known as a poor prognosis disease with a high degree of mortality. In Iran, it has been increased during the previous two decades, especially in northern part of the country. The aim of this study was to determine the demographic and clinical characteristics of gastric cancer in Mazandaran province. All patients with gastric cancer diagnosis treated in the Imam Khomeini educational hospital or Touba Polyclinic, a university affiliated center, from March ۲۰۰۸ to March ۲۰۱۴ were included. Demographic data, the symptoms at the time of presentation, tumor size, type of tumor, lymph node involvement, status in terms of metastatic disease, therapeutic plan and type of chemotherapy regimens were gathered from patients’ medical records. Statistical analysis was performed using SPSS, version ۱۶. Totally, ۶۴۳ patients were investigated. The mean age of patients was ۶۴.۳۴ years and men were more affected than women. “Time to relapse” and “time to progression” were ۱۳ and ۶.۵ months, respectively. The most common initial symptoms at diagnosis were nausea, vomiting and epigastric pain (۴۷.۴%). Only in ۶.۳%, the disease was diagnosed at the initial stages. The most common site of involvement was cardia (almost ۴۰%) and antrum (۳۲%). More than ۹۱% of tumors were adenocarcinoma. DCF (Docetaxel, Cisplatin, ۵FU) (۴۳.۳%), Xeloda (۱۵.۲%), DOX (Docetaxel, Oxaliplatin) (۱۳.۸%) and ECF (Epirubicin, Cisplatin.۵FU) (۹.۲%) were the most common used regimens. There was a trend for improved survival with DCF regimen (P = ۰.۰۸). Most gastric cancer patients were referred in the advanced stage or metastatic disease. The demographic characteristics are consistent with other previous reports. DCF regimen may have some advantages over other chemotherapy regimens.

Authors

Seyed Khalil Mousavi

Students Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Mazandaran, Sari. Iran.

Ghasem Janbabai

Department of Hematology and Oncology, Cancer Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran

Bizhan Kouchaki

Students Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Mazandaran, Sari. Iran

Hanieh Borhani

Cancer Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran

Masoumeh Rashidi

Cancer Research Center, Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Iran

Ebrahim Salehifar

Department of Clinical Pharmacy, Pharmaceutical Research Center, Mazandaran University of Medical Sciences, Sari, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Khushalani N. Cancer of the esophagus and stomach. Mayo Clinic ...
  • Movahedi M, Afsharfard A, Moradi A, Nasermoaddeli A,Khoshnevis J, Fattahia ...
  • Yazdannbod A, Arshi S, Derakhshan MH, Sadjadi AR,Malekzadeh R. Gastric ...
  • Yazdani Charati J, Zare S. Ghorbanpour E. Shabankhani B. Demographic ...
  • Naeeme SA, Naemeh S, Behzad M, Amir K. Mapping of ...
  • Catalano V. Labianca R, Beretta G, Gatta G, Braud F, ...
  • Woll E. Chemotherapy in Gastric Cancer. Anti Cancer Res ۲۰۰۸; ...
  • Biglaryan A. Hajizade A. Gohari M. Khodabakhshi R. Survival Analysis ...
  • Shafigh A. Siadati S. Shafayi Sh. Epidemiological studies of cancer ...
  • Roshanaei Gh. Kazemnejad A. Sadighi S. Assessment of the Survival ...
  • Akhavan A, Bashardoust N, Moghimi M, Seifadini A, Salehi M. ...
  • Moghimi-Dehkordi B, Rajaei Fard A, Tabatabaei H, Zeighami B, Safaee ...
  • Asmarian N, Kavousi A, Salehi M, Mahaki B. Mapping of ...
  • Keyhanian Sh, Farhadifar N, Fotoukian Z, Pouya M, Saravi M. ...
  • DavoodAbadi A, Sharifi H, Erfan N, Dianati M. An Epidemiologic ...
  • Somi M, Alizadeh N, Mirinezhad, SK, Jazeyeri E, Sadegi M, ...
  • Cutsem E, Moiseyenko V, Tjulandin S, Majlis A, Constenla M, ...
  • Ajani A. The role of docetaxel in gastric cancer. EJC ...
  • Sharifei H, Dianati M, Masoud A. A study on the ...
  • نمایش کامل مراجع